Search Results - "falcoz, antoine"

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice by Mouillet, Guillaume, Falcoz, Antoine, Fritzsch, Joëlle, Almotlak, Hamadi, Jacoulet, Pascale, Pivot, Xavier, Villanueva, Cristian, Mansi, Laura, Kim, Stefano, Curtit, Elsa, Meneveau, Nathalie, Adotevi, Olivier, Jary, Marine, Eberst, Guillaume, Vienot, Angelique, Calcagno, Fabien, Pozet, Astrid, Djoumakh, Oumelkheir, Borg, Christophe, Westeel, Virginie, Anota, Amélie, Paget-Bailly, Sophie

“…Introduction Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could…”
Get full text

Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review by Anota, Amélie, Pozet, Astrid, Lemasson, Hervé, Cotté, Francois-Emery, Falcoz, Antoine, Eberst, Guillaume, Mouillet, Guillaume, Guerzider, Stéphane, Charton, Émilie, Westeel, Virginie

“…Aim A systematic literature review of immuno-oncology trials was conducted to assess the potential impact of open-label vs double-blind trial design on…”
Get full text

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab by Jacquinot, Quentin, Meneveau, Nathalie, Falcoz, Antoine, Bouhaddi, Malika, Roux, Pauline, Degano, Bruno, Chatot, Marion, Curtit, Elsa, Mansi, Laura, Paillard, Marie-Justine, Bazan, Fernando, Chaigneau, Loïc, Dobi, Erion, Meynard, Guillaume, Vernerey, Dewi, Pivot, Xavier, Mougin, Fabienne

“…BackgroundTrastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer…”
Get full text

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial by Spehner, Laurie, Orillard, Emeline, Falcoz, Antoine, Lepiller, Quentin, Bouard, Adeline, Almotlak, Hamadi, Kim, Stefano, Curtit, Elsa, Meynard, Guillaume, Jary, Marine, Nardin, Charlee, Asgarov, Kamal, Abdeljaoued, Syrine, Chartral, Ugo, Mougey, Virginie, Ben Khelil, Myriam, Lopez, Morgane, Loyon, Romain, Vernerey, Dewi, Adotevi, Olivier, Borg, Christophe, Mansi, Laura, Kroemer, Marie

“…Objective Vaccinated patients with cancer in follow-up studies showed a high seropositivity rate but impaired antibody titres and T cell responses following…”
Get full text

KONO-S Anastomosis Is Not Superior to Conventional Anastomosis for the Reduction of Postoperative Endoscopic Recurrence in Crohn’s Disease by Tyrode, Gaëlle, Lakkis, Zaher, Vernerey, Dewi, Falcoz, Antoine, Clairet, Valentine, Alibert, Line, Koch, Stéphane, Vuitton, Lucine

“…Abstract Background Surgical resection rates remain high in Crohn’s disease (CD). Reducing postoperative recurrence (POR) is challenging. Besides drug therapy,…”
Get full text

A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial by Samaille, Thomas, Falcoz, Antoine, Cohen, Romain, Laurent-Puig, Pierre, André, Thierry, Taieb, Julien, Auclin, Edouard, Vernerey, Dewi

“…We assessed the added value of incorporating carcinoembryonic antigen (CEA) to circulating tumor DNA (ctDNA) and pathological TN (pTN) stage for risk…”
Get full text

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR) by Delattre, Jean-François, Cohen, Romain, Henriques, Julie, Falcoz, Antoine, Emile, Jean-François, Fratte, Serge, Chibaudel, Benoist, Dauba, Jérôme, Dupuis, Olivier, Bécouarn, Yves, Bibeau, Frédéric, Taieb, Julien, Louvet, Christophe, Vernerey, Dewi, André, Thierry, Svrcek, Magali

“…A post hoc analysis of all pathologic reports from patients with stage III CC included in the IDEA France phase III study (ClinicalTrials.gov identifier:…”
Get full text

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer by Rasola, Cosimo, Laurent-Puig, Pierre, André, Thierry, Falcoz, Antoine, Lepage, Come, Aparicio, Thomas, Bouché, Olivier, Lievre, Astrid, Mineur, Laurent, Bennouna, Jaafar, Louvet, Christophe, Bachet, Jean Baptiste, Borg, Christophe, Vernerey, Dewi, Lonardi, Sara, Taieb, Julien

“…It is intuitively thought that early relapse is associated with poor survival after recurrence (SAR) in resected colon cancer (CC) patients, but this has never…”
Get full text

1739: Local control patterns of GORTEC 2014-04 IIR Trial of SABR or chemo-SABR in oligometastastic HNSCCs by thariat, juliette, bosset, mathieu, falcoz, antoine, vernerey, dewi, pointreau, yoann, racadot, severine, faivre, jean christophe, castelli, joel, guihard, sebastien, huguet, florence, chapet, sophie, tao, yungan, maury, pauline, sayous, yann, bourhis, jean, sun, xu shan

Get full text

Natural history of patients with muscle metastases from renal cell carcinoma: Results of the French national ARTEMIS study by Wespiser, Mylene, Carril-Ajuria, Lucia, Ilfad, Blazevic, Thibault, Constance, Flechon, Aude, Martin, Sophie, Laramas, Mathieu, Borchiellini, Delphine, Simon, Camille, Mahammedi, Hakim, Linassier, Claude, Goujon, Morgan, Zaibet, Sonia, Rolland, Frederic, Albiges, Laurence, Meurisse, Aurelia, Falcoz, Antoine, Thiery-Vuillemin, Antoine

“…618 Background: Muscle metastases (MM) are among rare secondary locations in renal cell carcinoma (RCC). Current guidelines do not provide specific advice on…”
Get full text

Does Kono-S Anastomosis Reduce Recurrence in Crohn’s Disease Compared with Conventional Ileocolonic Anastomosis? A Nationwide Propensity Score-matched Study from GETAID Chirurgie Group [KoCoRICCO Study] by Alibert, Line, Betton, Louis, Falcoz, Antoine, Manceau, Gilles, Benoist, Stéphane, Zerbib, Philippe, Podevin, Juliette, Maggiori, Léon, Brouquet, Antoine, Tyrode, Gaëlle, Vuitton, Lucine, Vernerey, Dewi, Lefevre, Jérémie H, Lakkis, Zaher

“…Abstract Background and Aims Postoperative recurrence is a major concern in Crohn’s disease. The Kono-S anastomosis has been described to reduce the rate of…”
Get full text

Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study by Hammel, Pascal, Ben Abdelghani, Meher, Roth, Gael, Ulusakarya, Ayhan, Ghiringhelli, François, Toullec, Clemence, Borg, Christophe, Hentic Dhome, Olivia, Trouilloud, Isabelle, Dahan, Laetitia, Hiret, Sandrine, Bouche, Olivier, Rinaldi, Yves, Blanc, Jean-Frédéric, De La Fouchardiere, Christelle, Neuzillet, Cindy, Kamal, Maud, Falcoz, Antoine, Turpin, Anthony, Guimbaud, Rosine

“…673 Background: Maintenance treatments in m-PDAC patients (pts) after FFX induction is discussed. We assessed the efficacy of genetic-driven maintenance in pts…”
Get full text

Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study by Logeart, Juliette, Samaille, Thomas, Falcoz, Antoine, Svrcek, Magali, Dubreuil, Olivier, Vernerey, Dewi, Cohen, Romain, Cervera, Pascale, Valverde, Alain, Parc, Yann, André, Thierry

“…Stage II colon cancer (CC) exhibits considerable prognostic heterogeneous. Our objective was to assess survival but also the prognosis impact of microsatellite…”
Get full text

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability by Moreau, Mathilde, Alouani, Emily, Flecchia, Clémence, Falcoz, Antoine, Gallois, Claire, Auclin, Edouard, André, Thierry, Cohen, Romain, Hollebecque, Antoine, Turpin, Anthony, Pernot, Simon, Masson, Thérèse, Di Fiore, Frederic, Dutherge, Marie, Mazard, Thibault, Hautefeuille, Vincent, Van Laethem, Jean-Luc, De la Fouchardière, Christelle, Perkins, Géraldine, Ben-Abdelghani, Meher, Sclafani, Francesco, Aparicio, Thomas, Kim, Stefano, Vernerey, Dewi, Taieb, Julien, Guimbaud, Rosine, Tougeron, David

“…One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient…”
Get full text

Assessment of an emergency 14-day (d) integrative supportive care program (14-EISCP) followed by early chemotherapy (CTx) in symptomatic patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): A prospective ARCAD cohort study by Rousseau, Benoit, Falcoz, Antoine, Toullec, Clemence, Lecomte, Thierry, Lambert, Aurélien, Tournigand, Christophe, Guerin-Meyer, Veronique, Louvet, Christophe, Trouilloud, Isabelle, Rinaldi, Yves, Coriat, Romain, Dauba, Jerome, Neuzillet, Cindy, Andre, Thierry, Bachet, Jean-Baptiste, Cros, Jerome, De La Fouchardiere, Christelle, Garcia-Larnicol, Marie-Line, De Gramont, Aimery, Hammel, Pascal

“…700 Background: Pts with aPDAC often have general health impairment due to high symptom burden at diagnosis. We investigated prospectively the clinical benefit…”
Get full text

Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR) by Basile, D., Broudin, C., Emile, J.F., Falcoz, A., Pagès, F., Mineur, L., Bennouna, J., Louvet, C., Artru, P., Fratte, S., Ghiringhelli, F., André, T., Derangère, V., Vernerey, D., Taieb, J., Svrcek, M.

“…Histological characteristics at the invasive front may reflect tumor aggressiveness; specifically, tumor budding (Bd) is an emerging prognostic biomarker in…”
Get full text

Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study by Delaye, Matthieu, Assenat, Eric, Dahan, Laetitia, Blanc, Jean-Frédéric, Tougeron, David, Metges, Jean-Philippe, Lievre, Astrid, Turpin, Anthony, Fares, Nadim, De La Fouchardiere, Christelle, Castanie, Hélène, Desrame, Jérôme, Pellat, Anna, Lecomte, Thierry, Bignon, Anne Laure, Hautefeuille, Vincent, Garcia-Larnicol, Marie-Line, Falcoz, Antoine, Ben Abdelghani, Meher, Neuzillet, Cindy

“…4108 Background: D (anti-PDL1) plus T (anti-CTLA-4) combination immunotherapy showed encouraging results in hepato-biliary cancers. Its efficacy in non-Asian…”
Get full text

Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer by El Kaddissi, Antoine, Vernerey, Dewi, Falcoz, Antoine, Mansi, Laura, Bazan, Fernando, Chaigneau, Loïc, Dobi, Erion, Goujon, Morgan, Meneveau, Nathalie, Paillard, Marie-Justine, Selmani, Zohair, Viot, Julien, Molimard, Chloé, Monnien, Franck, Woronoff, Anne-Sophie, Curtit, Elsa, Borg, Christophe, Meynard, Guillaume

“…Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low…”
Get full text

Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study) by Alibert, Line, Betton, Louis, Falcoz, Antoine, Manceau, Gilles, Benoist, Stéphane, Zerbib, Philippe, Podevin, Juliette, Maggiori, Léon, Brouquet, Antoine, Tyrode, Gaëlle, Vuitton, Lucine, Vernerey, Dewi, Lefevre, Jérémie H., Lakkis, Zaher

“…Background and AimsPostoperative recurrence is a major concern in Crohn’s disease. The Kono-S anastomosis has been described to reduce the rate of recurrence…”
Get full text

Sidedness in metastatic colorectal carcinoma: Which are the factors which influence the prognosis? by Kogay, Maria, Evesque, Ludovic, Falcoz, Antoine, Saint, Angelique, Cavaglione, Gerard, Schiappa, Renaud, Baudin, Guillaume, Milano, Gerard A., Chamorey, Emmanuel, Francois, Eric

“…Abstract only 497 Background: Recent reports demonstrate prognostic and predictive impacts of the location of the primary tumor in metastatic colorectal cancer…”
Get full text